Buffington Mohr McNeal Decreases Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Buffington Mohr McNeal trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 18.8% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,714 shares of the medical research company's stock after selling 5,017 shares during the quarter. Thermo Fisher Scientific comprises about 2.1% of Buffington Mohr McNeal's investment portfolio, making the stock its 19th largest holding. Buffington Mohr McNeal's holdings in Thermo Fisher Scientific were worth $10,805,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of TMO. Bernard Wealth Management Corp. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $25,000. Pillar Financial Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $29,000. Ameriflex Group Inc. purchased a new position in Thermo Fisher Scientific in the 4th quarter worth $30,000. Cassady Schiller Wealth Management LLC lifted its position in Thermo Fisher Scientific by 89.2% during the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock worth $36,000 after acquiring an additional 33 shares during the period. Finally, VSM Wealth Advisory LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $36,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on TMO shares. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a report on Thursday, April 24th. UBS Group dropped their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Robert W. Baird cut their price target on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Finally, Wells Fargo & Company lowered their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $604.05.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president directly owned 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Trading Up 0.1%

Shares of TMO stock traded up $0.49 during trading hours on Friday, hitting $428.25. The company had a trading volume of 1,359,321 shares, compared to its average volume of 1,971,505. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. The company's fifty day moving average is $409.10 and its 200 day moving average is $480.59. The stock has a market capitalization of $161.66 billion, a PE ratio of 25.12, a price-to-earnings-growth ratio of 2.27 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company's quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the business posted $5.11 earnings per share. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.